These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12101266

  • 21. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G.
    Clin Cancer Res; 2005 Feb 15; 11(4):1490-9. PubMed ID: 15746051
    [Abstract] [Full Text] [Related]

  • 22. Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.
    Kaur H, Jaso-Friedmann L, Leary JH, Praveen K, Brahmi Z, Evans DL.
    Scand J Immunol; 2005 Oct 15; 62(4):361-70. PubMed ID: 16253123
    [Abstract] [Full Text] [Related]

  • 23. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE, Albritton KH, Bastar JD, Randall RL.
    J Orthop Res; 2006 Mar 15; 24(3):474-80. PubMed ID: 16450387
    [Abstract] [Full Text] [Related]

  • 24. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
    Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B.
    Oncogene; 2004 Jun 24; 23(29):4993-5003. PubMed ID: 15048072
    [Abstract] [Full Text] [Related]

  • 25. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C.
    Blood; 2000 Feb 01; 95(3):999-1006. PubMed ID: 10648415
    [Abstract] [Full Text] [Related]

  • 26. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
    Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A.
    Cancer Gene Ther; 1995 Sep 01; 2(3):207-12. PubMed ID: 8528964
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 28. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
    Campàs C, Cosialls AM, Barragán M, Iglesias-Serret D, Santidrián AF, Coll-Mulet L, de Frias M, Domingo A, Pons G, Gil J.
    Exp Hematol; 2006 Dec 01; 34(12):1663-9. PubMed ID: 17157163
    [Abstract] [Full Text] [Related]

  • 29. Phosphorothioate oligodeoxyribonucleotides induce in vitro proliferation of chicken B-cells.
    Wattrang E.
    Vet Immunol Immunopathol; 2009 Oct 15; 131(3-4):218-28. PubMed ID: 19447503
    [Abstract] [Full Text] [Related]

  • 30. [Apoptosis in chronic lymphocytic leukemia].
    Giordano M.
    Medicina (B Aires); 2000 Oct 15; 60 Suppl 2():12-6. PubMed ID: 11188924
    [Abstract] [Full Text] [Related]

  • 31. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia.
    Goolsby C, Paniagua M, Tallman M, Gartenhaus RB.
    Cytometry B Clin Cytom; 2005 Jan 15; 63(1):36-46. PubMed ID: 15624202
    [Abstract] [Full Text] [Related]

  • 32. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
    Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, Sica S, Leone G, Efremov DG.
    Leukemia; 2007 Jan 15; 21(1):110-20. PubMed ID: 17024114
    [Abstract] [Full Text] [Related]

  • 33. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS.
    Clin Cancer Res; 2005 Aug 15; 11(16):5950-5. PubMed ID: 16115938
    [Abstract] [Full Text] [Related]

  • 34. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J.
    Exp Hematol; 2008 Jan 15; 36(1):69-77. PubMed ID: 17959301
    [Abstract] [Full Text] [Related]

  • 35. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
    Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd J, Grever M, Marcucci G.
    Clin Cancer Res; 2005 Apr 15; 11(8):2998-3008. PubMed ID: 15837754
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma.
    Gabriel U, Bolenz C, Becker A, Schaaf A, Steidler A, Trojan L, Weiss C, Michel MS.
    Oncol Rep; 2008 Dec 15; 20(6):1419-23. PubMed ID: 19020723
    [Abstract] [Full Text] [Related]

  • 37. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
    Moon EY, Lerner A.
    Cancer Res; 2002 Oct 15; 62(20):5711-9. PubMed ID: 12384529
    [Abstract] [Full Text] [Related]

  • 38. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.
    Clin Cancer Res; 2003 Oct 01; 9(12):4595-605. PubMed ID: 14555535
    [Abstract] [Full Text] [Related]

  • 39. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
    Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H, Peschel C.
    Exp Hematol; 2000 May 01; 28(5):558-68. PubMed ID: 10812246
    [Abstract] [Full Text] [Related]

  • 40. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
    Zhang Z, Guo K, Schluesener HJ.
    J Neuroimmunol; 2005 Apr 01; 161(1-2):68-77. PubMed ID: 15748945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.